Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has
entered a new era, and the response rate and survival rate of many cancers have also been …

Over the last decade or so, there has been a paradigm shift in the oncologic care of patients
with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic …

Recent studies suggest that BRAF V600-mutated melanomas in particular respond to dual
anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T lymphocyte-associated …

Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …

Chimeric antigen receptor (CAR)-T cell therapy is the next revolutionary advance in cancer
therapy. By using ex vivo engineered T cells to specifically target antigens, a targeted …

Immune checkpoint inhibitors (ICIs) are an effective therapy for various cancers; however,
they can induce immune-related adverse events (irAEs) as a side effect. Myocarditis is an …

BACKGROUND: Immune checkpoint inhibitors (ICIs), antibodies targeting PD-1
(programmed cell death protein 1)/PD-L1 (programmed death-ligand 1) or CTLA4 (cytotoxic …

Background and Purpose Immune checkpoint inhibitors (ICI), such as anti‐PD‐1
monoclonal antibodies, have revolutionized cancer therapy by enhancing the cytotoxic …

Cardiovascular disease (CVD) and cancer are the leading causes of death worldwide. With
an increasing number of the elderly population, and early cancer screening and treatment …

Immune checkpoint inhibitors (ICIs) have been increasingly used in combination for cancer
treatment but are associated with myocarditis. Here, we report that tumor-bearing mice …